Efficacy of Budesonide-Formoterol in Bronchiectasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-01-31

Study Completion Date

2005-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Some studies have concluded that high-dose inhaled steroids (IS) are effective in the clinical control of patients with bronchiectasis, however the high doses needed provokes some adverse effects and lower doses are not effective. Combined treatment with budesonide and formoterol have demostrated to be effective in patients with asthma and COPD achieving the reduction of steroid dose thanks to the adition of a long-acting beta 2 agonists. There are no studies in the literature analysing the effect of combined treatment in patients with bronchiectasis. The objective of this study is to compare the efficacy and safety of formoterol-medium dose of budesonide in a single inhaler versus high-dose of budesonide in the clinical control of patientes with non-cystic fibrosis bronchiectasis.

Study Design:

Randomized (3 months) parallel groups study.

Patients:

Patients with bronchiectasis diagnosed by high-resolution CT scan and chronic obstructive airway obstruction.

Exclusion:

Asthma and current or past smokers.

Methods:

Run in period in all patients with high dose of budesonide (1600 mcg/day) for 3 months. After that, randomization into two groups: 1. The same treatment (1600 mcg/day of budesonide) or combined treatment with lower dose of budesonide (18 mcg/day of formoterol and 800 mcg of budesonide) in a single turbuhaler inhaler during 3 months.

Studied variables:

Clinical, functional, quality of life, microbiological and number of side effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Budesonide / Formoterol in Treatment of Exacerbations of COPD

NCT00239278

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis

NCT01769898

Bronchiectasis

COMPLETED PHASE4

Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

NCT00476099

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE3

Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial

NCT03846570

Bronchiectasis

TERMINATED PHASE3

Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder

NCT01738087

Asthmatic

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchiectasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Medium Dose of budesonide-formoterol

Group Type EXPERIMENTAL

budesonide-formoterol single inhaler

Intervention Type DRUG

High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid

High dose of budesonide

Intervention Type DRUG

1600 mcg/d of budesonide

A

Intervention Type DRUG

medium dose of budesonide-formoterol

B

High dose of inhaled budesonide (1600 mcg/day)

Group Type ACTIVE_COMPARATOR

budesonide-formoterol single inhaler

Intervention Type DRUG

High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid

High dose of budesonide

Intervention Type DRUG

1600 mcg/d of budesonide

B

Intervention Type DRUG

High Dose Inhaled Budesonide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

budesonide-formoterol single inhaler

High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid

Intervention Type DRUG

High dose of budesonide

1600 mcg/d of budesonide

Intervention Type DRUG

A

medium dose of budesonide-formoterol

Intervention Type DRUG

B

High Dose Inhaled Budesonide

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

B. High-dose budesonide arm A. Medium dose of budesonide plus formoterol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-80 years old patients diagnosed of non-cystic fibrosis bronchiectasis
* More than 1 pulmonary lobe affected
* Chronic obstructive airflow obstruction
* Stable phase of the disease